COMMUNIQUÉS West-GlobeNewswire
-
Civitas Networks for Health to Host 2024 Annual Conference in Detroit This October
28/03/2024 - 18:29 -
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
28/03/2024 - 19:00 -
Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call
28/03/2024 - 16:45 -
UPDATE – Breckenridge Brewery Partners With Denver Nuggets to Launch Championship Edition Mile High City Golden Ale
28/03/2024 - 17:50 -
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
28/03/2024 - 13:00 -
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
28/03/2024 - 13:00 -
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
28/03/2024 - 13:00 -
IMUNON Reports 2023 Financial Results and Provides Business Update
28/03/2024 - 13:00 -
QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
28/03/2024 - 13:00 -
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
28/03/2024 - 13:00 -
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
28/03/2024 - 13:00 -
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28/03/2024 - 13:00 -
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
28/03/2024 - 13:00 -
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
28/03/2024 - 13:00 -
Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2023 Financial and Operational Results
28/03/2024 - 13:00 -
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
28/03/2024 - 13:01 -
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28/03/2024 - 13:03 -
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
28/03/2024 - 13:05 -
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28/03/2024 - 13:05
Pages